Related Experiment Videos
A site-specific controlled-release system for metformin
Giacomo Di Colo1, Ylenia Zambito, Andrea Baggiani
1Department of Bioorganic Chemistry and Biopharmaceutics, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy. giadic@farm.unipi.it
The Journal of Pharmacy and Pharmacology
|May 20, 2005
Summary
This study developed a novel controlled-release metformin hydrochloride matrix. The optimized formulation ensures complete drug release in the upper intestine, potentially improving bioavailability and reducing side effects.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Metformin hydrochloride (MF-HCl) absorption is limited to the upper intestine.
- Controlled-release formulations are needed to optimize MF-HCl delivery.
Purpose of the Study:
- To prepare a novel matrix system for sustained release of high MF-HCl doses.
- To ensure complete drug release within the stomach to jejunum transit.
Main Methods:
- Matrices were prepared by compressing varying ratios of MF-HCl and Precirol ATO 5.
- A face of the matrix was coated with Eudragit L100-55.
- Drug release was evaluated in sequential simulated gastric, jejunal, and ileal fluids.
Main Results:
- Drug release was dependent on drug load but independent of pH and hydrodynamics.
- Release kinetics followed a radical t type, governed by drug diffusion.
- A half-coated matrix demonstrated complete release in simulated gastric and jejunal fluids.
Conclusions:
- The developed half-coated matrix synchronizes MF-HCl release with intestinal transit.
- This formulation approach may enhance drug bioavailability.
- This controlled-release strategy has the potential to reduce metformin-related side effects.